From April 21 to 23, CPhI Japan 2026 was successfully held at Tokyo Big Sight. As a renowned exhibition in the field of pharmaceutical raw materials in Japan and even across Asia, this event gathered exhibitors and professional visitors from numerous countries and regions worldwide, building a platform for innovative communication and supply chain connection in the pharmaceutical industry. Sichuan Xieli Pharmaceutical showcased its competitive APIs and natural extract products portfolio. Leveraging superior product quality and industrial chain advantages, Xieli actively engaged with the Japanese and global pharmaceutical markets and successfully completed this exhibition participation.
With long-term dedication to the healthcare industry, Xieli Pharma fully adheres to international GMP guidelines. Guided by the corporate mission of “Uniting Efforts for Global Health”, we have built an integrated industrial system of source-side cultivation--R&D and manufacturing--international regulatory registration --global distribution. We strive to deliver fully compliant, internationally recognized products and professional services to clients worldwide.
During the exhibition, Xieli Pharma highlighted three core business segments: Natural-origin APIs, oncology APIs and customized CDMO service. A wide range of flagship products were showcased, including Rutin/Troxerutin series, Hesperidin/Diosmin series and Irinotecan Hydrochloride. In addition, backed by our in-house herbal planting bases and integrated traditional Chinese medicine preparation production capabilities, we further promoted our Kampo medicine business in Japan and received highly positive feedback from local markets.
At our booth, our professional team offered in-depth consultations for global visitors on product profiles, quality specifications and global registration status. We attracted continuous inquiries and business discussions from prospects across Japan, Europe, America and Southeast Asia. Our internationally recognized certifications, including PMDA, FDA, EU-GMP and MHRA, were highly acknowledged by clients, laying a solid foundation for deeper cooperation and further market expansion in Japan.
As a key market for global pharmaceutical R&D and manufacturing, Japan enforces strict standards for API quality and regulatory compliance. Through this exhibition, Xieli Pharma fully demonstrated our standardized manufacturing capabilities and product competitiveness, closely aligning with local market demands and securing solid ground for future partnership development.
Moving forward, we will further strengthen our strategic layout in Japan: accelerate overseas registration and certification for more product lines to enrich localized supply; optimize sourced side cultivation and full-track traceability systems to meet Japan’s high-end quality requirements; and leverage our professional CDMO expertise to provide one-stop customized services, from process development to commercial-scale production, for clients in Japan and beyond.
CPhI Japan 2026 has concluded successfully, marking another steady step in Xieli’s global development strategy. From Pengzhou manufacturing base to the exhibition floor in Tokyo, from deep roots in the Chinese market to an expanding global footprint, Xieli will always uphold the highest standards of compliance and product quality. We drive pharmaceutical innovation through the power of nature and connect global health through reliable, compliant services.
We sincerely appreciate every customer and partner who visit our booth. Moving forward, we hope to join hands for long-term cooperation, explore new prospects across the pharmaceutical industry, and jointly create a promising future for global healthcare.
